This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations
This person is not affiliated with any business or Blue Board record at ProZ.com.
Services
Translation, Interpreting, Editing/proofreading, Subtitling, Training
Expertise
Specializes in:
Biology (-tech,-chem,micro-)
Medical (general)
Medical: Health Care
Medical: Instruments
Medical: Pharmaceuticals
Medical: Cardiology
Also works in:
Chemistry; Chem Sci/Eng
Idioms / Maxims / Sayings
More
Less
Rates
English to Spanish - Standard rate: 0.10 USD per word / 34 USD per hour Portuguese to Spanish - Standard rate: 0.10 USD per word / 34 USD per hour Spanish to English - Standard rate: 0.10 USD per word / 34 USD per hour Spanish to Portuguese - Standard rate: 0.10 USD per word / 34 USD per hour
English to Spanish: Original Article General field: Medical Detailed field: Science (general)
Source text - English Original Article
The New England Journal of Medicine
Indacaterol–Glycopyrronium versus
Salmeterol–Fluticasone for COPD
Jadwiga A. Wedzicha, M.D., Donald Banerji, M.D., Kenneth R. Chapman, M.D., Jorgen Vestbo, M.D., D.M.Sc., Nicolas Roche, M.D., R. Timothy Ayers, M.Sc., Chau Thach, Ph.D., Robert Fogel, M.D., Francesco Patalano, M.D., and Claus F. Vogelmeier, M.D., for the FLAME Investigators*
ABSTRACT
BACKGROUND
Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the firstchoice treatment for patients with chronic obstructive pulmonary disease (COPD) who have a high risk of exacerbations. The role of treatment with a LABA–LAMA
regimen in these patients is unclear.
METHODS
We conducted a 52-week, randomized, double-blind, double-dummy, noninferiority trial. Patients who had COPD with a history of at least one exacerbation during the previous year were randomly assigned to receive, by inhalation, either the
LABA indacaterol (110 μg) plus the LAMA glycopyrronium (50 μg) once daily or the LABA salmeterol (50 μg) plus the inhaled glucocorticoid fluticasone (500 μg) twice daily. The primary outcome was the annual rate of all COPD exacerbations.
RESULTS
A total of 1680 patients were assigned to the indacaterol–glycopyrronium group, and 1682 to the salmeterol–fluticasone group. Indacaterol–glycopyrronium showed not only noninferiority but also superiority to salmeterol–fluticasone in reducing the
annual rate of all COPD exacerbations; the rate was 11% lower in the indacaterol–glycopyrronium group than in the salmeterol–fluticasone group (3.59 vs. 4.03; rate ratio, 0.89; 95% confidence interval [CI], 0.83 to 0.96; P = 0.003). The indacaterol–glycopyrronium group had a longer time to the first exacerbation than did the salmeterol–fluticasone group (71 days [95% CI, 60 to 82] vs. 51 days [95% CI, 46 to 57]; hazard ratio, 0.84 [95% CI, 0.78 to 0.91], representing a 16% lower risk; P
Translation - Spanish ARTICULO ORIGINAL
The New England Journal of Medicine
Indacaterol-Glycopirronio versus Salmeterol-Fluticasona para el tratamiento de la EPOC
Jadwiga A. Wedzicha, MD, Donald Banerji, MD, Kenneth R. Chapman, MD, Jorgen Vestbo, MD, DMSc., Nicolas Roche, MD, R. Timoteo Ayers, M.Sc., Chau Thach, Ph.D., Robert Fogel, MD, Francesco Patalano, MD, y Noel F. Vogelmeier, MD, por los investigadores FLAME *
RESUMEN
ANTECEDENTES
La mayoría de las guías recomienda ya sea la combinación de beta-agonistas de acción prolongada (Long Acting Beta Agonistis - LABA) más un glucocorticoide inhalatorio, o un antagonista muscarínico de acción prolongada (Long Acting Muscarinic Antagonist - LAMA) como tratamiento de primera línea para pacientes con enfermedad pulmonar obstructiva crónica (EPOC) que presentan alto riesgo de exacerbaciones. La efectividad del tratamiento con un régimen combinado de LABA-LAMA en estos pacientes no está clara.
MÉTODOS
Llevamos a cabo un estudio de no-inferioridad de 52 semanas, aleatorio, doble ciego, con doble simulación. Pacientes con diagnóstico de EPOC e historia de al menos una exacerbación durante el año anterior fueron asignados al azar para recibir, por vía inhalatoria, ya sea la combinación del LABA indacaterol (110 mcg) más el LAMA glicopirronio (50 mcg) una vez al día, o la combinación del LABA salmeterol (50 mcg) más el glucocorticoide inhalatorio fluticasona (500 mcg) dos veces al día. La medida de resultado primaria fue la tasa anual de todas las exacerbaciones de EPOC.
RESULTADOS
Un total de 1680 pacientes fué asignado al grupo de indacaterol-glicopirronio y 1682 al grupo de salmeterol-fluticasona. La combinación indacaterol-glicopirronio mostró no sólo no inferioridad, sino superioridad a la combinación salmeterol-fluticasona en la reducción de la tasa anual de todas las exacerbaciones de EPOC; la tasa fue 11% menor en el grupo indacaterol-glicopirronio que en el grupo salmeterol-fluticasona (3,59 vs. 4,03; cociente de tasas, 0,89; intervalo de confianza [IC] 95%, 0,83 a 0,96; P = 0,003). El grupo indacaterol-glicopirronio presentó un período mayor hasta la primera exacerbación que el grupo salmeterol-fluticasona (71 días [IC del 95%, 60 a 82] vs. 51 días [IC del 95%, del 46 a 57]; cociente de riesgo, 0,84 [IC del 95%, 0,78 a 0,91], lo que representa una reducción del riesgo del 16%; P
More
Less
Experience
Years of experience: 15. Registered at ProZ.com: Jan 2002.
English to Spanish (Cambridge University (ESOL Examinations)) Spanish to English (Cambridge University (ESOL Examinations)) Portuguese to Spanish (Doctor of Medicine, UNIRIO, RJ, Brazil) Spanish to Portuguese (Doctor of Medicine, UNIRIO, RJ, Brazil)
Memberships
N/A
Software
Adobe Acrobat, MateCat, Microsoft Excel, Microsoft Word, Powerpoint
Bio
Medical Doctor trained in Brazil and specialized in the United States in the areas of Internal Medicine, Pulmonary and Critical Care Medicine
This user has earned KudoZ points by helping other translators with PRO-level terms. Click point total(s) to see term translations provided.
Expertise